Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43974   clinical trials with a EudraCT protocol, of which   7311   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2017-003675-61
    Sponsor's Protocol Code Number:D3252C00001
    National Competent Authority:Austria - BASG
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2017-11-30
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedAustria - BASG
    A.2EudraCT number2017-003675-61
    A.3Full title of the trial
    A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study Of Benralizumab in Patients with Severe Nasal Polyposis
    Eine multizentrische, randomisierte, doppelblinde, Placebo-kontrollierte Parallelgruppenstudie der Phase 3 zu Wirksamkeit und Sicherheit von Benralizumab bei Patienten mit schwergradigen Nasenpolypen (OSTRO)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Efficacy and Safety Study of Benralizumab for Patients with Severe Nasal Polyposis
    A.3.2Name or abbreviated title of the trial where available
    OSTRO
    A.4.1Sponsor's protocol code numberD3252C00001
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAstraZeneca AB
    B.1.3.4CountrySweden
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportSponsor
    B.4.2CountrySweden
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAstraZeneca AB
    B.5.2Functional name of contact pointInformation Center
    B.5.3 Address:
    B.5.3.1Street AddressVastra Malarehamnen 9
    B.5.3.2Town/ citySödertälje
    B.5.3.3Post code151 85
    B.5.3.4CountrySweden
    B.5.6E-mailinformation.center@astrazeneca.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBenralizumab administered via accessorized pre-filled syringe (APFS)
    D.3.2Product code MEDI-563
    D.3.4Pharmaceutical form Solution for injection in pre-filled syringe
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBenralizumab
    D.3.9.1CAS number 1044511-01-4
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number30
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Yes
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection in pre-filled syringe
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Nasal polyposis
    E.1.1.1Medical condition in easily understood language
    Nasal polyposis (NP) is a chronic inflammatory disease of the nasal mucosa characterized by the presence of polyps in the upper nasal cavity.
    E.1.1.2Therapeutic area Diseases [C] - Respiratory Tract Diseases [C08]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10028754
    E.1.2Term Nasal polyp
    E.1.2System Organ Class 100000004855
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the effect of benralizumab on nasal polyp burden and patient-reported nasal blockage
    E.2.2Secondary objectives of the trial
    To evaluate the effect of benralizumab on:
    - disease specific health-related quality of life (HRQoL)
    - nasal polyp surgery and/or SCS use
    - sense of smell
    - systemic corticosteroids (SCS) use for relief of nasal symptoms
    - symptoms associated with nasal polyps
    - sinus opacification by computed tomography (CT) scan (subset of patients)
    - proportion of NP surgery
    - patient-reported general health status

    Safety objectives:
    - to assess the safety of benralizumab
    - to assess the pharmacokinetics and immunogenicity of benralizumab
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions, listed in the informed consent form (ICF) and in protocol.
    2. Provision of signed and dated, written informed consent form (ICF) prior to any mandatory study specific procedures, sampling, and analyses and according to international guidelines and/or applicable EU guidelines.
    3. Provision of signed and dated written genetic informed consent in patients that agree to participate in the genetic sampling, prior to collection of sample for genetic analysis.
    4. Female or male patients aged 18 to 75 years inclusive, at the time of signing the ICF.
    5. Patients with bilateral sinonasal polyposis that, despite treatment
    with a stable dose of intranasal corticosteroids (INCS) for at least 4
    weeks prior to V1, in addition to a history of treatment with systemic
    corticosteroids (SCS -oral, parenteral) or prior surgery for nasal
    polyposis (NP), have severity consistent with a need for surgery as
    described by:
    - A minimum total Nasal Polyp Score (NPS) of 5 out of a maximum score
    of 8 (with a unilateral score of at least 2 for each nostril) at V1 and
    continuously maintained at V2 to meet the randomization criterion, as
    determined by the study Imaging Core Lab;
    - Ongoing symptoms for at least 12 weeks prior to V1;
    - Patient-reported moderate to severe nasal blockage score (NBS) 2 or 3
    over the 2-weeks prior to V1 (2-week recall assessment of symptoms,
    scores 0-none to 3-severe).
    6. SNOT-22 total score ≥ 30 at enrolment (V1).
    Patient must meet the following criteria (points 7-10) at the
    randomization visit (V3):
    7. At least 8 days of evaluable daily diary data in the 14-day period prior
    to randomization (baseline bi-weekly mean score collected from study
    Day -13 to study Day 0).
    8. At randomization, a bi-weekly mean NBS ≥ 1.5.
    9. SNOT-22 total score ≥ 30 at randomization (V3).
    10. At least 70% compliance with INCS during the run-in period based
    on daily diary.
    11. Patients with a minimum weight of 40kg.
    12. Negative serum pregnancy test result at V1 and a negative urine
    pregnancy test at randomization for female patients of childbearing
    potential.
    13. Women of childbearing potential (WOCBP) must use an effective
    form of birth control (confirmed by the Investigator) eg, total sexual
    abstinence, a vasectomized sexual partner, Implanon. Female
    sterilization by tubal occlusion, any effective IUD intrauterine
    device/IUS levonorgestrel Intrauterine system, Depo-ProveraTM
    injections, oral contraceptive, Evra PatchTM, or NuvaringTM. Women of
    childbearing potential must agree to use highly effective method of birth
    control, as defined above, from enrolment, throughout the study
    duration and for 16 weeks after the last dose of investigational product
    (IP).
    14. Women not of childbearing potential are defined as women who are
    either permanently sterilized (hysterectomy, bilateral oophorectomy, or
    bilateral salpingectomy), or who are postmenopausal. Women will be
    considerd postmenopausal if they have been amenorrheic for 12 months
    prior to the planned date of the randomization without alternative
    medical cause. The following age specific requirements apply:
    - Women <50 years old are considered postmenopausal if they have
    been amenorrheic for 12 months or more following cessation of
    exogenous hormonal treatment and if follicle stimulating hormone (FSH)
    levels are in the postmenopausal range;
    - Women ≥ 50 years old are considered postmenopausal if they have
    been amenorrheic for 12 months or more following cessation of all
    exogenous hormonal treatment.
    15. Male subjects who are sexually active must be surgically sterile at
    least one year prior to Visit 1 or must use an adequate method of
    contraception (condom or condom with spermicide depending on local
    regulations) from the first dose of IP until 16 weeks after their last dose.
    Men with a partner or partners who is (are) not of childbearing potential
    are exempt of these requirements.
    E.4Principal exclusion criteria
    1. Patients who have undergone any nasal and/or sinus surgery within 3months prior to V1
    2. Patients with conditions or concomitant disease that makes them non evaluable for the co-primary efficacy endpoint such as:
    - Unilateral antrochoanal polyps;
    - Nasal septal deviation that occludes at least one nostril;
    - Acute sinusitis, nasal infection, or upper respiratory infection at
    screening or in the 2 weeks before screening;
    - Current rhinitis medicamentosa;
    - Allergic fungal rhinosinusitis (AFRS) or Allergic fungal sinusitis (AFS);
    - Nasal cavity tumors
    3. Clinically important comorbidities that could confound Interpretation of clinical efficacy results including, but not limited to: active upper or lower respiratory tract infection, cystic fibrosis, primary ciliary dyskinesia, eosinophilic diseases other than asthma (eg, allergic bronchopulmonary aspergillosis/mycosis, eosinophilic granulomatosis with polyangitis [Churg-Strauss syndrome], hypereosinophilic syndromes), granulomatosis with polyangitis (Wegener's granulomatosis), Young's syndrome, etc.
    4. Any disorder, including but not limited to: cardiovascular,
    gastrointestinal, hepatic, renal, neurological, musculoskeletal,
    infectious, endocrine, metabolic, haematological, psychiatric, or Major physical impairment that is not stable in the opinion of the Investigator or AstraZeneca and could:
    - Affect the safety of the patient throughout the study;
    - Influence the findings of the studies or their interpretations;
    - Impede the patient's ability to complete the entire duration of study
    5. Patients experiencing an asthma exacerbation requiring systemic
    (oral and/or parenteral) corticosteroids treatment or hospitalization
    (>24hrs) for treatment of asthma within 4 weeks prior to V1
    6. History of anaphylaxis to any biologic therapy or vaccine
    7. Known history of allergy or reaction to any component of the IP
    formulation
    8. History of Guillain-Barré syndrome
    9. A helminth parasitic infection diagnosed within 24 weeks prior to V1 and has not been treated with, or has failed to respond to standard of care therapy
    10. Current malignancy, or history of malignancy with specific
    exceptions
    11. Any clinically significant cardiac disease or any electrocardiogram
    (ECG) abnormality obtained during the screening/run-in period, which may put the patient at risk or interfere with study assessments
    12. Positive hepatitis B surface antigen, or hepatitis C virus antibody
    serology (confirmed by additional testing, e.g. hepatitis C RNA test, if
    indicated), or a positive medical history for hepatitis B or C. (Note:
    Patients with history of hepatitis B vaccination without history of
    hepatitis B are allowed to enrol)
    13. History of known immunodeficiency disorder, including a positive
    human immunodeficiency virus (HIV) test
    14. Infection requiring systemic antibiotics (Ab) within 14 days prior to V1
    15. Use of immunosuppressive medication (including but not limited to: methotrexate, troleandomycin, cyclosporine, azathioprine, or any
    experimental anti-inflammatory therapy) within 3 months prior to V1
    16. Receipt of any marketed or investigational biologic products
    (monoclonal or polyclonal antibody) within 6 months or 5 half-lives,
    whichever is longer, prior to V1. This also applies to patients who
    previously participated in clinical studies and were treated with
    monoclonal antibodies (e.g. mepolizumab, reslizumab, dupilumab,
    omalizumab). Note that this restriction do not apply to patients, who are confirmed to have only received treatment with placebo
    17. Previous receipt of benralizumab
    18. Receipt of immunoglobulin or blood products within 30 days prior to V1
    19. Receipt of live attenuated vaccines 30 days prior to the date of
    randomization
    20. Receipt of any investigational drug within 30 days or 5 half-lives
    whichever is longer prior to randomization
    21. Receipt of systemic corticosteroid 4 weeks prior to V1, or a
    scheduled systemic corticosteroid treatment during the study period
    NOTE: Sustained release steroids (e.g. Kenalog [Triamcinolone
    acetonide]) or depot injections require minimum 6 weeks washout Prior to V1
    22. Receipt of leukotriene antagonist/modifiers for patients who were not on a continuous stable dose for ≥30 days prior to V1
    23. Concurrent enrolment in another clinical drug interventional trial
    24. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥ 3 times the upper limit of normal (ULN) confirmed during screening period
    25. Previous randomization in the present study
    26. Planned major surgical procedures or scheduled NP surgery at the time of the study enrolment and randomization
    27. Initiated or is being maintained on an aspirin desensitization
    regimen for the management of AERD (aspirin exacerbated respiratory disease) at the time of study enrolment or during the run in period
    28. For women only – currently pregnant (or intend to become
    pregnant), breastfeeding or lactating
    E.5 End points
    E.5.1Primary end point(s)
    - change from baseline in endoscopic total nasal polyp score
    - change from baseline in mean nasal blockage score
    E.5.1.1Timepoint(s) of evaluation of this end point
    - change from baseline at Week 56
    E.5.2Secondary end point(s)
    - change from baseline in SinoNasal Outcome Test (SNOT-22) score
    - time to first NP surgery
    - time to first NP surgery and/or SCS use for NP
    - sense of smell captured as change from baseline in mean difficulty with
    sense of smell (DSS) score
    - sense of smell captured as change from baseline in University of
    Pennsylvania Smell Identification Test (UPSIT) score
    - change from baseline in Lund Mackay score and sinus severity score by
    Quantitative CT analysis (subset of patients)
    - proportion of patients with surgery for NP
    - proportion of patients with SCS use for NP
    - time to first SCS course for NP, number of courses of SCS for NP, total
    SCS dose used and total duration of SCS use for NP
    - change from baseline in nasal symptom score(s) as captured in the
    daily diary
    - change from baseline in Short Form 36-item Health survey, Version 2
    (SF-36v2), Physical Component Score (PCS), Mental Component Score
    (MCS) and domains
    - adverse events and serious adverse events
    - laboratory variables
    - serum PK
    - benralizumab anti-drug antibodies
    E.5.2.1Timepoint(s) of evaluation of this end point
    - following the first administration of study drug through week 56
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Approx.1st 200Pts who complete treatment enter 6mths FollowUP.CT done in Pts subset at chosen sites
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA28
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Austria
    Belgium
    Canada
    Denmark
    Hungary
    Poland
    Sweden
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last expected visit/contact of the last patient undergoing the study.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months11
    E.8.9.1In the Member State concerned days12
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months11
    E.8.9.2In all countries concerned by the trial days12
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 350
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 50
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state36
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 258
    F.4.2.2In the whole clinical trial 400
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-01-04
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-12-13
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2020-07-31
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA